Andrew A. F. Hack

Andrew A. F. Hack (board member) discloses dealings in 6 companies, chiefly Editas Medicine, Inc., Mersana Therapeutics, Inc. and Dynavax Technologies Corp. Over a trading history stretching from 11 January 2017 to 6 January 2026, the count stands at 81 filings.

The open-market side counts 14 purchases for €52.9M alongside 32 sales for €209.9M. Taken together, the sales exceed the purchases by €157.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants and 26 option exercises.

The median purchase comes to €4.4M. On 3 out of 14 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 6 January 2026, the filings show a transaction in Mersana Therapeutics, Inc. The latest purchase dates back some time: it was published 1,448 days ago, on 3 November 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.